Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study

Inflammatory Bowel Disease

IFNγ-producing CD8⁺ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis

Gastroenterology

Sasson SC, Slevin SM, Cheung VT, Nassiri I, Olsson-Brown A, Fryer E, Ferreira RC, Trzupek D, Gupta T, Al-Hillawi L, Issaias ML, Easton A, Campo L, FitzPatrick ME, Adams J, Chitnis M, Protheroe A, Tuthill M, Coupe N, Simmons A, Payne M, Middleton MR, Travis SP, Oxford IBD Cohort Investigators., Fairfax BP, Klenerman P, Brain O

doi: 10.1053/j.gastro.2021.06.025

Inflammatory Bowel Disease

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study

Inflamm Bowel Dis.

Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Jr

doi: 10.1093/ibd/izx076.

COMMENTED

Inflammatory Bowel Disease

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

J Crohns Colitis.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A, GETAID.

doi: 10.1093/ecco-jcc/jjz088.

COMMENTED

Inflammatory Bowel Disease

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Int J Colorectal Dis.

Novello M, Stocchi L, Holubar S, Shawki S, Lipman J, Gorgun E, Hull T, Steele SR

doi: 10.1007/s00384-018-3212-6.

Further Publications

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study

Clin Gastroenterol Hepatol

Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen V, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin K, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch A, Viveiros K, Chan W, Chascsa D, Kwo P, Dhanasekaran R

doi: 10.1016/j.cgh.2020.09.027

COMMENTED

Inflammatory Bowel Disease

Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

Inflamm Bowel Dis.

Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS

doi: 10.1093/ibd/izy307.

Inflammatory Bowel Disease

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis

J Crohns Colitis.

Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L

doi: 10.1093/ecco-jcc/jjz029.

Gastrointestinal Cancer

Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Hepatology.

Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR

doi: 10.1002/hep.31227.

Inflammatory Bowel Disease

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

United European Gastroenterol J.

Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F

doi: 10.1177/2050640619895361.

Related content

IFNγ-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study

Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis

Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

IFNγ-producing CD8⁺ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis